Renee Lentini Biography and Net Worth

Insider of ImmunoGen

Renee Lentini is the VP of Fin., Principal Accounting Officer & Corp. Controller at Immunogen.

What is Renee Lentini's net worth?: The estimated net worth of Renee Lentini is at least $0.00 as of December 26th, 2023. Ms. Lentini owns 8,452 shares of ImmunoGen stock worth more than $0 as of April 6th. This net worth estimate does not reflect any other assets that Ms. Lentini may own. Learn More about Renee Lentini's net worth.
How do I contact Renee Lentini?: The corporate mailing address for Ms. Lentini and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at courtney.okonek@immunogen.com. Learn More on Renee Lentini's contact information.
Has Renee Lentini been buying or selling shares of ImmunoGen?: Renee Lentini has not been actively trading shares of ImmunoGen over the course of the past ninety days. Most recently, Renee Lentini sold 6,548 shares of the business's stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $29.74, for a transaction totalling $194,737.52. Following the completion of the sale, the vice president now directly owns 8,452 shares of the company's stock, valued at $251,362.48. Learn More on Renee Lentini's trading history.
Who are ImmunoGen's active insiders?: ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (President, CEO & Director), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.

Renee Lentini Insider Trading History at ImmunoGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/26/2023	Sell	6,548	$29.74	$194,737.52	8,452
11/6/2023	Sell	219,545	$15.29	$3,356,843.05
8/2/2023	Sell	148,277	$17.55	$2,602,261.35	22,843

Renee Lentini Buying and Selling Activity at ImmunoGen

ImmunoGen Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Today's Range

Now: N/A

50 Day Range

MA: $31.23

$31.23

2 Week Range

Now: N/A

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield